FrancophonIA/ELRC3.0 huggingface dataset:
English: UNIQUE IDENTIFIER - 2D BARCODE 2D barcode carrying the unique identifier included 18.
Croatian: Sadrži 2D barkod s jedinstvenim identifikatorom
English: Among entecavir-treated nucleoside naive patients, post-treatment exacerbations had a median time to onset of 23-24 weeks, and most were reported in HBeAg negative patients (see section 4.8).
Croatian: Kod bolesnika liječenih entekavirom prethodno neliječenih analozima nukleozida, egzacerbacije nakon prestanka liječenja nastupile su nakon medijana od 23-24 tjedna, a većina je bila prijavljena u HBeAg negativnih bolesnika (vidjeti dio 4.8).
English: *p value vs lamivudine <0.05 a patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score ≥2) b a primary endpoint c Roche Cobas Amplicor PCR assay (LLOQ = 300 copies/ml)
Croatian: *p vrijednost naspram lamivudina < 0,05 a bolesnici s ocjenjivim histološkim nalazom na početku ispitivanja (početni Knodellov indeks nekroze i upale ≤ 2) b primarni ishod c Roche Cobas Amplicor PCR test (LLOQ = 300 kopija/ml)
English: Occurrences of lactic acidosis (in the absence of hypoxaemia), sometimes fatal, usually associated with severe hepatomegaly and hepatic steatosis, have been reported with the use of nucleoside analogues.
Croatian: S primjenom analoga nukleozida prijavljene su pojave laktacidoze (u odsutnosti hipoksemije), ponekad sa smrtnim ishodom i obično povezane s teškom hepatomegalijom i jetrenom steatozom.
English: Hepatic impairment: no dose adjustment is required in patients with hepatic impairment.
Croatian: Oštećenje funkcije jetre: nije potrebna prilagodba doze u bolesnika s oštećenjem funkcije jetre.
English: Experience in patients co-infected with HIV
Croatian: Iskustvo u bolesnika istodobno inficiranih HIV-om
English: Entecavir Mylan is only available as 0.5 and 1 mg film-coated tablets.
Croatian: Entekavir Mylan dostupan je samo u obliku filmom obloženih tableta od 0,5 i 1 mg.
English: Nucleoside Naive HBeAg Positive (study 022)
Croatian: Prethodno neliječeni analozima nukleozida HBeAg pozitivni (ispitivanje 022)
English: It is not known whether entecavir, the active ingredient in Entecavir Mylan, is excreted in human breast milk.
Croatian: Nije poznato izlučuje li se entekavir, djelatna tvar u lijeku Entekavir Mylan, u majčino mlijeko.
English: A higher rate of serious hepatic adverse events (regardless of causality) has been observed in patients with decompensated liver disease, in particular in those with Child-Turcotte-Pugh (CTP) class C disease, compared with rates in patients with compensated liver function.
Croatian: U bolesnika s dekompenziranom bolešću jetre, osobito u onih s bolešću kategoriziranom po ChildTurcotte-Pugh (CTP) klasifikaciji kao bolest klase C, opažena je viša stopa ozbiljnih jetrenih nuspojava (bez obzira na uzrok) u usporedbi sa stopama u bolesnika s kompenziranom funkcijom jetre.
English: Exacerbations during treatment
Croatian: Egzacerbacije tijekom liječenja
English: Acute exacerbation of hepatitis has also been reported in patients who have discontinued hepatitis B therapy (see section 4.2).
Croatian: Akutna egzacerbacija hepatitisa prijavljena je i u bolesnika koji su prekinuli terapiju hepatitisa B (vidjeti dio 4.2).
English: Liver transplant recipients
Croatian: Primatelji transplantata jetre
English: The steady-state pharmacokinetics of entecavir were evaluated (study 028) in 24 nucleoside naïve and 19 lamivudine-experienced HBeAg-positive paediatric subjects from 2 to <18 years of age with compensated liver disease.
Croatian: Farmakokinetika entekavira u stanju dinamičke ravnoteže ocijenjena je (ispitivanje 028) u 24 pedijatrijska ispitanika koji prethodno nisu bili liječeni analozima nukleozida i 19 HBeAg pozitivnih pedijatrijskih ispitanika prethodno liječenih lamivudinom, koji su bili u dobi od 2 do < 18 godina i imali kompenziranu bolest jetre.
English: Acute exacerbations of hepatitis have been reported in patients who have discontinued anti-hepatitis B virus therapy, including therapy with entecavir (see section 4.4).
Croatian: Akutne egzacerbacije hepatitisa prijavljene su u bolesnika koji su prekinuli terapiju protiv virusa hepatitisa B, uključujući terapiju entekavirom (vidjeti dio 4.4).
English: For 26 entecavir-treated and 28 lamivudine-treated patients who continued treatment beyond 52 weeks (median 96 weeks), 96% of entecavir-treated and 64% of lamivudine-treated patients had HBV DNA <300 copies/ml by PCR at end of dosing.
Croatian: Za 26 bolesnika liječenih entekavirom i 28 bolesnika liječenih lamivudinom koji su nastavili liječenje nakon 52. tjedna (medijan 96 tjedana), 96% bolesnika liječenih entekavirom i 64% bolesnika liječenih lamivudinom imalo je HBV DNK < 300 kopija/ml mjereno PCR-om na kraju doziranja.
English: * p value vs lamivudine <0.05 a patients with evaluable baseline histology (baseline Knodell Necroinflammatory Score ≥ 2) b a primary endpoint.
Croatian: * p vrijednost naspram lamivudina < 0,05 a bolesnici s ocjenjivim histološkim nalazom na početku ispitivanja (početni Knodellov indeks nekroze i upale ≤ 2) b primarni ishod.
English: Ishak fibrosis score improvement Ishak fibrosis score worsening n
Croatian: Pogoršanje prema Ishakovom indeksu fibroze n
English: If you forget to take Entecavir Mylan
Croatian: Ako ste zaboravili uzeti lijek Entekavir Mylan
English: 4.5 Interaction with other medicinal products and other forms of interaction Since entecavir is predominantly eliminated by the kidney (see section 5.2), coadministration with medicinal products that reduce renal function or compete for active tubular secretion may increase serum concentrations of either medicinal product.
Croatian: Kako se entekavir najvećim dijelom eliminira bubrezima (vidjeti dio 5.2), istodobna primjena lijekova koji smanjuju funkciju bubrega ili se natječu za aktivnu tubularnu sekreciju može povećati koncentraciju jednog ili drugog lijeka u serumu.
English: Among entecavir-treated nucleoside-naive patients, ALT elevations had a median time to onset of 23-24 weeks, and 86% (24/28) of ALT elevations occurred in HBeAg negative patients.
Croatian: Među bolesnicima liječenima entekavirom prethodno neliječenima analozima nukleozida, povišenja ALT-a nastupila su nakon medijana od 23-24 tjedna, a u 86% (24/28) slučajeva povišenje ALT-a nastupilo je u HBeAg negativnih bolesnika.
English: PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR BLISTERS
Croatian: PODACI KOJI SE MORAJU NALAZITI NA VANJSKOM PAKIRANJU KARTONSKA KUTIJA ZA BLISTERE
English: Age/gender
Croatian: Dob/spol
English: Renal function should be carefully evaluated before and during entecavir therapy in liver transplant recipients receiving cyclosporine or tacrolimus (see section 5.2).
Croatian: Kod primatelja transplantata jetre koji primaju ciklosporin ili takrolimus treba pažljivo procijeniti funkciju bubrega prije i tijekom terapije entekavirom (vidjeti dio 5.2).
English: Entecavir Mylan should be taken orally.
Croatian: Entekavir Mylan se uzima peroralno.
English: Therefore, appropriate interventions should be used to prevent neonatal acquisition of HBV. Breast-feeding
Croatian: Stoga je potrebno poduzeti odgovarajuće postupke kako bi se spriječio neonatalni prijenos HBV-a.
English: You should not breast-feed during treatment with Entecavir Mylan.
Croatian: Ne smijete dojiti tijekom liječenja lijekom Entekavir Mylan.
English: Laboratory test abnormalities: through week 48 among entecavir-treated patients with decompensated liver disease, none had ALT elevations both >10 times ULN and >2 times baseline, and 1% of patients had ALT elevations >2 times baseline together with total bilirubin >2 times ULN and >2 times baseline.
Croatian: Abnormalnosti laboratorijskih nalaza: do 48. tjedna niti jedan od bolesnika liječenih entekavirom s dekompenziranom bolešću jetre nije imao povišenja ALT > 10 puta iznad GGN i > 2 puta iznad početne vrijednosti, a 1% bolesnika imao je povišenja ALT > 2 puta iznad početne vrijednosti s ukupnim bilirubinom > 2 puta iznad GGN i > 2 puta iznad početne vrijednosti.
English: Relative to the adverse reactions noted in section Tabulated list of adverse reactions, one additional adverse reaction [decrease in blood bicarbonate (2%)] was observed in entecavir-treated patients through week 48.
Croatian: Tablični prikaz nuspojava, opažena je jedna dodatna nuspojava [sniženje bikarbonata u krvi (2%)] u bolesnika liječenih entekavirom do 48. tjedna.
English: Patients with decompensated liver disease
Croatian: Bolesnici s dekompenziranom bolešću jetre
English: Children weighing at least 32.6 kg may take the 0.5 mg tablet or an entecavir oral solution may be available.
Croatian: Djeca tjelesne težine od najmanje 32,6 kg mogu uzimati tabletu od 0,5 mg ili oralnu otopinu entekavira ukoliko je dostupna.
English: Entecavir has not been evaluated in HIV/HBV co-infected patients not concurrently receiving effective HIV treatment.
Croatian: Entekavir se nije ispitivao u bolesnika istodobno inficiranih HIV-om i HBV-om koji nisu istodobno primali učinkovitu terapiju za HIV.
English: • In HBeAg negative adult patients, treatment should be administered at least until HBs seroconversion or there is evidence of loss of efficacy.
Croatian: • Kod HBeAg negativnih odraslih bolesnika, liječenje se mora primjenjivati barem do HBs serokonverzije ili dokazanog gubitka djelotvornosti.
English: Experience in lamivudine-refractory patients with compensated liver disease
Croatian: Iskustvo u bolesnika refrakternih na lamivudin s kompenziranom bolešću jetre
English: Lamivudine-refractory or decompensated liver disease
Croatian: Bolest refrakterna na lamivudin ili dekompenzirana bolest jetre
English: In studies in nucleoside-naive patients, 6% of entecavir-treated patients and 10% of lamivudine-treated patients experienced ALT elevations (>10 times ULN and >2 times reference [minimum of baseline or last end-of-dosing measurement]) during post-treatment follow-up.
Croatian: U ispitivanjima u bolesnika prethodno neliječenih analozima nukleozida, 6% bolesnika liječenih entekavirom i 10% bolesnika liječenih lamivudinim imalo je povišenja ALT-a (> 10 puta iznad GGN i > 2 puta iznad referentne vrijednosti [minimalno od početne vrijednosti ili posljednjeg mjerenja na kraju doziranja]) tijekom praćenja nakon prestanka liječenja.
English: Dosage adjustment is recommended for patients with renal impairment (see section 4.2).
Croatian: Preporučuje se prilagoditi dozu kod bolesnika s oštećenjem funkcije bubrega (vidjeti dio 4.2).
English: a NC=F (noncompleter = failure) * Patients randomised to placebo who did not have HBe serconversion by Week 48 rolled over to open-label entecavir for the second year of the study; therefore randomised comparison data are available only through Week 48.
Croatian: Početna vrijednost HBV DNK < 8 log10 IU/ml Početna vrijednost HBV DNK ≤ 8 log10 IU/ml a NC=F (nedovršeno = neuspjeh) * Bolesnici randomizirani za primanje placeba koji nisu postigli HBe- serokonverziju do 48. tjedna prešli su na otvoreno liječenje entekavirom tijekom druge godine ispitivanja; stoga su podaci o randomiziranoj usporedbi dostupni samo do 48. tjedna.
English: At end of dosing, among patients who continued treatment beyond 52 weeks (median of 96 weeks), 81% of 243 entecavir-treated and 39% of 164 lamivudine-treated patients had HBV DNA <300 copies/ml by PCR while ALT normalisation (≤1 times ULN) occurred in 79% of entecavirtreated and 68% of lamivudine-treated patients.
Croatian: Na kraju doziranja, među bolesnicima koji su nastavili liječenje nakon 52. tjedna (medijan 96 tjedana), 81% od 243 bolesnika liječenih entekavirom i 39% od 164 bolesnika liječenih lamivudinom imalo je HBV DNK < 300 kopija/ml mjereno PCR-om, dok je normalizacija ALT-a (≥ 1 puta iznad GGN) nastupila u 79% bolesnika liječenih entekavirom i 68% liječenih lamivudinom.
English: Spontaneous exacerbations in chronic hepatitis B are relatively common and are characterised by transient increases in serum ALT. After initiating antiviral therapy, serum ALT may increase in some patients as serum HBV DNA levels decline (see section 4.8).
Croatian: Nakon početne antivirusne terapije, u nekih se bolesnika serumska ALT može povisiti kako se serumske razine HBV DNK snizuju (vidjeti dio 4.8).
English: No data are available on the efficacy of entecavir in HBeAgnegative patients co-infected with HIV.
Croatian: Nema dostupnih podataka o djelotvornosti entekavira kod HBeAg-negativnih bolesnika istodobno inficiranih HIV-om.
English: For the 77 patients who continued entecavir treatment beyond 52 weeks (median 96 weeks), 40% of patients had HBV DNA <300 copies/ml by PCR and 81% had ALT normalisation (≤1 times ULN) at end of dosing.
Croatian: Od 77 bolesnika koji su nastavili liječenje entekavirom nakon 52. tjedna (medijan 96 tjedana), 40% imalo je HBV DNK < 300 kopija/ml mjereno PCR-om, a 81% je imalo normalizaciju ALT-a (≥ 1 puta iznad GGN) na kraju doziranja.
English: The Cmax, AUC(0-24), and Cmin for these subjects was 14.48 ng/ml, 38.58 ng·h/ml, and 0.47 ng/ml, respectively.
Croatian: U tih je ispitanika Cmax iznosio 14,48 ng/ml, AUC(0-24) 38,58 ng·h/ml, a Cmin 0,47 ng/ml.
English: Human immunodeficiency virus (HIV)/HBV co-infected patients not receiving concomitant antiretroviral therapy
Croatian: Bolesnici istodobno inficirani virusom humane imunodeficijencije (HIV) i HBV-om koji istodobno ne primaju antiretrovirusnu terapiju
English: Among entecavir-treated patients ontreatment exacerbations had a median time of onset of 4-5 weeks.
Croatian: Među bolesnicima koji se liječe entekavirom, egzacerbacije su nastupile s medijanom od 4-5 tjedana.
English: The Cmax, AUC (0-24), and Cmin for these subjects was 6.31 ng/ml, 18.33 ng h/ml, and 0.28 ng/ml, respectively.
Croatian: U tih je ispitanika Cmax iznosio 6,31 ng/ml, AUC (0-24) 18,33 ng·h/ml, a Cmin 0,28 ng/ml.
English: • In HBeAg negative paediatric patients, treatment should be administered until HBs seroconversion or there is evidence of loss of efficacy.
Croatian: • Kod HBeAg negativnih pedijatrijskih bolesnika liječenje treba primjenjivati do HBs serokonverzije ili do znakova gubitka djelotvornosti.
English: Albumin levels <2.5 g/dl occurred in 30% of patients, lipase levels >3 times baseline in 10% and platelets <50,000/mm3 in 20%.
Croatian: Razine albumina < 2,5 g/dl izmjerene su u 30% bolesnika, razine lipaze > 3 puta iznad početne vrijednosti u 10% i trombociti < 50 000/mm3 u 20% bolesnika.
English: In studies in lamivudine-refractory patients, with only limited numbers of patients being followed up, 11% of entecavir-treated patients and no lamivudine-treated patients developed ALT elevations during post-treatment follow-up.
Croatian: U ispitivanjima u bolesnika s hepatitisom refrakternim na lamivudin, kad se pratio samo ograničen broj bolesnika, povišenja ALT-a tijekom praćenja nakon liječenja nastupila su u 11% bolesnika liječenih entekavirom i niti u jednog bolesnika liječenog lamivudinom.
English: Stable or improved CTP scoreb,d MELD score
Croatian: Stabilan ili poboljšan CTP indeksb,d Srednja vrijednost promjene MELD bodova u odnosu na početne vrijednostic,e Nestanak HBsAgb
English: Lamivudine-refractory
Croatian: Refrakterni na lamivudin
English: For lamivudine (n = 355), cumulative response rates were 39% for HBV DNA <300 copies/ml by PCR, 79% for ALT normalisation, 26% for HBeAg seroconversion, and 2% for HBsAg seroconversion (3% for HBsAg loss).
Croatian: Kumulativne stope odgovora na liječenje lamivudinom (n = 355) bile su 39% za HBV DNK < 300 kopija/ml mjereno PCR-om, 79% za normalizaciju ALT, 26% za HBeAg serokonverziju i 2% za HBsAg serokonverziju (3% za nestanak HBsAg).
English: PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING BOTTLE LABEL
Croatian: PODACI KOJI SE MORAJU NALAZITI NA UNUTARNJEM PAKIRANJU NALJEPNICA ZA BOČICU
English: Compensated liver disease
Croatian: Dekompenzirana bolest jetre
English: Emerging Genotypic Entecavir Resistance Through Year 5, Nucleoside-Naïve Studies
Croatian: Pojava genotipske rezistencije na entekavir do kraja 5. godine ispitivanja u bolesnika prethodno neliječenih analozima nukleozida
English: Also, lamivudine-refractory patients who achieved HBV DNA <104 log10 copies/ml by PCR at Week 24 had a lower rate of resistance than those who did not (5-year cumulative probability 17.6% [n= 50] versus 60.5% [n= 135], respectively).
Croatian: tjednu imali su nižu stopu rezistencije od onih koji nisu postigli tu vrijednost (5-godišnja kumulativna vjerojatnost od 17,6% [n= 50] naspram 60,5% [n= 135]).
English: Following administration of 14C-entecavir, no oxidative or acetylated metabolites and minor amounts of the phase
Croatian: entekavira nisu opaženi ni oksidirani ili acetilirani metaboliti niti manje količine metabolita faze II, glukuronidni i sulfatni konjugati.
English: Severe Managed with CAPD (n = 4)
Croatian: Teško, liječeni KAPD-om (n = 4)
English: ALT (≤1 X ULN)b
Croatian: ALT (≥ 1 X GGN)b
English: These trials provide experience in 195 HBeAg-positive nucleosidetreatment-naïve subjects treated with entecavir for a median duration of 99 weeks.
Croatian: Ova su ispitivanja pružila iskustvo liječenja entekavirom tijekom medijana od 99 tjedana u 195 HBeAg pozitivnih ispitanika koji prethodno nisu bili liječeni analozima nukleozida.
English: There is a dose-proportionate increase in Cmax and AUC values following multiple doses ranging from 0.1-1 mg. Steady-state is achieved between 610 days after once daily dosing with ≈ 2 times accumulation.
Croatian: Postoji dozi proporcionalno povećanje vrijednosti Cmax i AUC-a nakon primjene višekratnih doza u rasponu od 0,1-1 mg.
English: Albumin levels <2.5 g/dl occurred in <1% of patients, amylase levels >3 times baseline in 2%, lipase levels >3 times baseline in 11% and platelets <50,000/mm3 in <1%.
Croatian: Razine albumina < 2,5 g/dl bile su prisutne u < 1% bolesnika, razine amilaze > 3 puta iznad početne vrijednosti bile su prisutne u 2%, razine lipaze > 3 puta iznad početne vrijednosti pronašle su se u 11%, a trombociti < 50 000/mm3 u < 1% bolesnika.
English: PHARMACEUTICAL FORM AND CONTENTS Tablet
Croatian: OBLIK I SADRŽAJ
English: Talk to your doctor or pharmacist before taking Entecavir Mylan if you have ever had problems with your kidneys, tell your doctor.
Croatian: Obratite se svom liječniku ili ljekarniku prije nego uzmete Entekavir Mylan
English: In clinical studies with nucleoside-naive patients, 5% had ALT elevations >3 times baseline, and <1% had ALT elevations >2 times baseline together with total bilirubin >2 times upper limit of normal
Croatian: U kliničkim ispitivanjima u bolesnika prethodno neliječenih analozima nukleozida, 5% je imalo povišen ALT > 3 puta iznad početne vrijednosti, a < 1% imalo je povišenja ALT-a > 2 dva puta iznad početne vrijednosti zajedno s ukupnim bilirubinom povišenim > 2 puta iznad gornje granice normale (GGN) i > 2 puta iznad početne vrijednosti.
English: Bilirubin (≤1 X ULN)b
Croatian: Bilirubin (≥ 1 X GGN)b
English: Exacerbations of hepatitis during and after discontinuation of entecavir therapy have also been reported (see section 4.4 and Description of selected adverse reactions).
Croatian: Također su prijavljene egzacerbacije hepatitisa tijekom i nakon prekida terapije entekavirom (vidjeti dio 4.4 i c.
English: When starting therapy in patients with a documented history of lamivudineresistant HBV, combination use of entecavir plus a second antiviral agent (which does not share crossresistance with either lamivudine or entecavir) should be considered in preference to entecavir monotherapy.
Croatian: Prilikom započinjanja terapije u bolesnika s dokumentiranom HBV-rezistencijom na lamivudin, treba razmotriti i dati prednost kombiniranoj uporabi entekavira s drugim antivirusnim lijekom (koji ne dijeli križnu rezistenciju bilo s lamivudinom bilo s entekavirom) naspram monoterapije entekavirom.
English: In clinical studies with lamivudine-refractory patients, 4% had ALT elevations >3 times baseline, and <1% had ALT elevations >2 times baseline together with total bilirubin >2 times ULN and >2 times baseline.
Croatian: U kliničkim ispitivanjima u bolesnika refrakternih na lamivudin, 4% bolesnika imalo je povišenja ALT-a > 3 puta iznad početne vrijednosti, a < 1% je imalo povišen ALT > 2 puta iznad početne vrijednosti zajedno s ukupnim bilirubinom > 2 puta iznad GGN i > 2 puta iznad početne vrijednosti.
English: Amylase levels >3 times baseline occurred in 2% of patients, lipase levels >3 times baseline in 18% and platelets <50,000/mm3 in <1%.
Croatian: Razine amilaze > 3 puta iznad početne vrijednosti javile su se u 2% bolesnika, razine lipaze > 3 puta iznad početne vrijednosti u 18% i trombociti < 50 000/mm3 u < 1% bolesnika.
English: * for doses <0.5 mg entecavir oral solution is recommended ** on haemodialysis days, administer entecavir after haemodialysis.
Croatian: * Za doze < 0,5 mg preporučuje se oralna otopina entekavira.
English: HIV/HBV co-infected patients receiving concomitant antiretroviral therapy
Croatian: Bolesnici istodobno inficirani HIV-om i HBV-om koji istodobno primaju antiretrovirusnu terapiju
English: HBeAg negative (study 027): treatment with entecavir up to 96 weeks (n = 325) resulted in cumulative response rates of 94% for HBV DNA <300 copies/ml by PCR and 89% for ALT normalisation versus 77% for HBV DNA <300 copies/ml by PCR and 84% for ALT normalisation for lamivudine-treated patients (n = 313).
Croatian: HBeAg negativni (ispitivanje 027): liječenje entekavirom u trajanju do 96 tjedana (n = 325) rezultiralo je kumulativnim stopama odgovora od 94% za HBV DNK < 300 kopija/ml mjereno PCR-om i 89% za normalizaciju ALT-a, naspram kumulativne stope odgovora na liječenje lamivudinom (n = 313) od 77% za HBV DNK < 300 kopija/ml mjereno PCR-om i 84% za normalizaciju ALT-a.
English: Entecavir dosage* Nucleoside naïve patients
Croatian: Doza entekavira* Bolesnici prethodno neliječeni analozima nukleozida
English: Viral load reduction (log10 copies/ml)c HBV DNA undetectable (<300 copies/ml by PCR)c ALT normalisation (≤1 times ULN) HBeAg Seroconversion
Croatian: HBV DNK nemjerljiva (< 300 kopija/ml pomoću PCR)c Normalizacija ALT (≥ 1 puta GGN)
English: An oral solution should be used for patients with body weight less than 32.6 kg.
Croatian: Za bolesnike tjelesne težine manje od 32,6 kg treba primijeniti oralnu otopinu.
English: Entecavir
Croatian: Apsorpcija
English: Adefovir Dipivoxil 10 mg once daily n
Croatian: Adefovir dipivoksil 10 mg jednom dnevno n HBV DNKa
English: Each film-coated tablet contains entecavir monohydrate equivalent to 1 mg entecavir.
Croatian: Jedna filmom obložena tableta sadrži entekavir hidrat što odgovara 1 mg entekavira.
English: Viral load reduction (log10 copies/ml)c HBV DNA undetectable (<300 copies/ml by PCR)c
Croatian: HBV DNK nemjerljiva (< 300 kopija/ml pomoću PCR)c
English: Entecavir Mylan 0.5 mg film-coated tablets Entecavir Mylan 1 mg film-coated tablets
Croatian: Entekavir Mylan 0,5 mg filmom obložene tablete Entekavir Mylan 1 mg filmom obložene tablete
English: Moderate (n = 6)
Croatian: Umjereno (n = 6)
English: Each film-coated tablet contains entecavir monohydrate equivalent to 0.5 mg entecavir.
Croatian: Jedna filmom obložena tableta sadrži entekavir hidrat što odgovara 0,5 mg entekavira.
English: HBeAg positive (study 022): treatment with entecavir for up to 96 weeks (n = 354) resulted in cumulative response rates of 80% for HBV DNA <300 copies/ml by PCR, 87% for ALT normalisation, 31% for HBeAg seroconversion and 2% for HBsAg seroconversion (5% for HBsAg loss).
Croatian: HBeAg pozitivni (ispitivanje 022): kumulativne stope odgovora na liječenje entekavirom u trajanju do 96 tjedana (n = 354) bile su 80% za HBV DNK < 300 kopija/ml mjereno PCR-om, 87% za normalizaciju ALT, 31% za HBeAg serokonverziju i 2% za HBsAg serokonverziju (5% za nestanak HBsAg).
English: In studies with lamivudine-refractory patients, on treatment ALT elevations >10 times ULN and >2 times baseline occurred in 2% of entecavir treated patients vs 11% of lamivudine treated patients.
Croatian: U ispitivanjima u bolesnika refrakternih na lamivudin, ALT koji se za vrijeme liječenja povisio > 10 puta iznad GGN i > 2 puta iznad početnih vrijednosti javio se u 2% bolesnika liječenih entekavirom i 11% bolesnika liječenih lamivudinom.
English: Severe (n = 6)
Croatian: Teško (n = 6)